Vai al contenuto principale
keyboard_return Invio

Valeant Pharmaceuticals to Acquire Bausch + Lomb for $8.7 Billion

Valeant Pharmaceuticals to Acquire Bausch + Lomb for $8.7 Billion

LAVAL, Quebec and ROCHESTER, NY—Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Bausch + Lomb Holdings Incorporated, the global eye health company, announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash, according to an announcement from B+L.   Valeant Pharmaceuticals is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of products primarily in the areas of dermatology, neurology and branded generics.   Read the article on VMail
Back